STOCK TITAN

Syndax Pharmaceuticals Inc - SNDX STOCK NEWS

Welcome to our dedicated news page for Syndax Pharmaceuticals (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syndax Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syndax Pharmaceuticals's position in the market.

Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) will report its Q4 and year-end 2023 financial results and provide a business update on February 27, 2024. A conference call and webcast will be held to discuss the financial results and business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) announced the granting of inducement awards to purchase up to 127,300 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) will participate in two upcoming investor conferences, the Guggenheim 6th Annual Biotechnology Conference and the Citi 2024 Virtual Oncology Leadership Summit. The management team will engage in fireside chats on February 8th and February 21st, 2024, respectively. The live webcast of the events can be accessed from the Investor section of the Company's website at www.syndax.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
conferences
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) announces the grant of inducement awards to a new employee under the 2023 Inducement Plan, allowing the purchase of up to 8,600 shares of common stock. The stock options will vest over four years, subject to the employee's continued service relationship with Syndax.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The CEO, Michael A. Metzger, will discuss the company's innovative pipeline of cancer therapies. The event will be live webcasted and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) highlights recent updates and anticipated 2024 milestones, including the submission of BLA for axatilimab in chronic graft-versus-host disease, NDA for revumenib in R/R KMT2Ar acute leukemia, and completion of a $230 million follow-on offering in December extending the runway through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) closed a public offering of 12,432,431 shares of common stock, generating approximately $230.0 million in gross proceeds. The company now has 84,809,736 shares issued and outstanding as of December 19, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
-
Rhea-AI Summary
Syndax Pharmaceuticals, Inc. (SNDX) has announced the pricing of an underwritten public offering of 10,810,810 shares of its common stock at $18.50 per share. The aggregate gross proceeds from this offering are expected to be approximately $200.0 million. The offering is expected to close on December 19, 2023. Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
-
Rhea-AI Summary
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) plans to offer $150 million of common stock in an underwritten public offering, with an option for underwriters to purchase an additional 15%. The shares will be sold by Syndax and offered pursuant to an automatically effective 'shelf' registration statement previously filed with the SEC. Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) presented positive data from the pivotal AUGMENT-101 trial of revumenib at the 65th American Society of Hematology Annual Meeting. The trial met its primary endpoint, with a 63% overall response rate and a median overall survival of 8.0 months. The safety profile was favorable, and responses were observed across all major subgroups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
Syndax Pharmaceuticals Inc

Nasdaq:SNDX

SNDX Rankings

SNDX Stock Data

1.85B
84.63M
0.82%
106.63%
11.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About SNDX

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.